Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesis

Wen,Binhong; Zhao,Lu; Zhao,Hongmei; Wang,Xiaochen

doi:10.3892/etm.2018.6043

Liraglutide exerts a bone‑protective effect in ovariectomized rats with streptozotocin‑induced diabetes by inhibiting osteoclastogenesis

Authors:
- Binhong Wen
- Lu Zhao
- Hongmei Zhao
- Xiaochen Wang
View Affiliations

Affiliations: Department of Endocrinology, The People's Hospital of China Medical University, The People's Hospital of Liaoning Province, Shenyang, Liaoning 110016, P.R. China
Published online on: April 10, 2018 https://doi.org/10.3892/etm.2018.6043
Pages: 5077-5083

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liraglutide, a glucagon‑like peptide‑1 receptor agonist, is an anti‑diabetic medicine associated with a reduced risk of fracture in diabetic patients. In the present study, rats with streptozotocin (STZ)‑induced diabetes and/or bilateral ovariectomy (OVX) were treated with liraglutide for eight weeks. Liraglutide treatment increased insulin secretion and managed blood glucose levels in the rats following STZ‑induced diabetes. In addition, STZ‑ and OVX‑induced reduction of femoral bone mineral density and destruction of bone microarchitecture were alleviated by liraglutide. STZ decreased, whereas OVX increased, serum osteocalcin (OC) level (a bone formation marker) and osteoblast counts in the trabecular bone. OVX, however not STZ, markedly increased the level of serum c‑terminal telopeptide of type 1 collagen (CTX‑1, a bone resorption marker) and osteoclast counts in the trabecular area. Liraglutide treatment significantly increased serum OC levels in all three osteoporotic models, however had minimal effects on osteoblast counts. Furthermore, liraglutide significantly decreased serum CTX‑1 level and osteoclast numbers in OVX and STZ+OVX rats. Furthermore, the present study examined the mRNA expression and serum concentrations of osteoprotegerin (OPG) and receptor activator of nuclear factor‑κB ligand (RANKL), and liraglutide significantly decreased the RANKL/OPG ratio compared with the untreated rats, indicating that osteoclastogenesis was inhibited by liraglutide. In summary, the results suggested that liraglutide ameliorates STZ+OVX‑induced bone deterioration in the rat model, primarily through the inhibition of osteoclastogenesis. These preliminary findings propose a potentially beneficial effect of liraglutide on the bone health of postmenopausal diabetic patients.

View Figures

View References

1	Vestergaard P: Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 18:427–444. 2007. View Article : Google Scholar : PubMed/NCBI
2	Janghorbani M, Van Dam RM, Willett WC and Hu FB: Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 166:495–505. 2007. View Article : Google Scholar : PubMed/NCBI
3	Grey A: Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 19:129–137. 2008. View Article : Google Scholar : PubMed/NCBI
4	Rachner TD, Khosla S and Hofbauer LC: Osteoporosis: Now and the future. Lancet. 377:1276–1287. 2011. View Article : Google Scholar : PubMed/NCBI
5	Zaidi M: Skeletal remodeling in health and disease. Nat Med. 13:791–801. 2007. View Article : Google Scholar : PubMed/NCBI
6	Berberoglu Z, Yazici AC and Demirag NG: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: A 2-year follow-up study. Clin Endocrinol (Oxf). 73:305–312. 2010. View Article : Google Scholar : PubMed/NCBI
7	Heilmeier U, Carpenter DR, Patsch JM, Harnish R, Joseph GB, Burghardt AJ, Baum T, Schwartz AV, Lang TF and Link TM: Volumetric femoral BMD, bone geometry and serum sclerostin levels differ between type 2 diabetic postmenopausal women with and without fragility fractures. Osteoporos Int. 26:1283–1293. 2015. View Article : Google Scholar : PubMed/NCBI
8	Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ and Christiansen C: Four-month treatment with GLP-2 significantly increases hip BMD: A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone. 45:833–842. 2009. View Article : Google Scholar : PubMed/NCBI
9	Nicodemus KK and Folsom AR: Iowa Women's Health Study: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 24:1192–1197. 2001. View Article : Google Scholar : PubMed/NCBI
10	Nauck MA: Incretin-based therapies for type 2 diabetes mellitus: Properties, functions and clinical implications. Am J Med. 124 Suppl 1:S3–S18. 2011. View Article : Google Scholar : PubMed/NCBI
11	Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S and Wang J: Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: A meta-analysis of randomized controlled trials. Endocrine. 48:107–115. 2015. View Article : Google Scholar : PubMed/NCBI
12	Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jørgensen NR, Jensen JE, Holst JJ, Madsbad S and Torekov SS: GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 100:2909–2917. 2015. View Article : Google Scholar : PubMed/NCBI
13	Mansur SA, Mieczkowska A, Bouvard B, Flatt PR, Chappard D, Irwin N and Mabilleau G: Stable incretin mimetics counter rapid deterioration of bone quality in type 1 diabetes mellitus. J Cell Physiol. 230:3009–3018. 2015. View Article : Google Scholar : PubMed/NCBI
14	Sun HX, Lu N, Luo X, Zhao L and Liu JM: Liraglutide, the glucagon-like peptide-1 receptor agonist, has anabolic bone effects in diabetic Goto-Kakizaki rats. J Diabetes. 7:584–588. 2015. View Article : Google Scholar : PubMed/NCBI
15	Lu N, Sun H, Yu J, Wang X, Liu D, Zhao L, Sun L, Zhao H, Tao B and Liu J: Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes. PLoS One. 10:e01327442015. View Article : Google Scholar : PubMed/NCBI
16	Pereira M, Jeyabalan J, Jorgensen CS, Hopkinson M, Al-Jazzar A, Roux JP, Chavassieux P, Orriss IR, Cleasby ME and Chenu C: Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice. Bone. 81:459–467. 2015. View Article : Google Scholar : PubMed/NCBI
17	Lasota A and Danowska-Klonowska D: Experimental osteoporosis-different methods of ovariectomy in female white rats. Rocz Akad Med Bialymst. 49 Suppl 1:S129–S131. 2004.
18	Moon YJ, Yun CY, Choi H, Ka SO, Kim JR, Park BH and Cho ES: Smad4 controls bone homeostasis through regulation of osteoblast/osteocyte viability. Exp Mol Med. 48:e2562016. View Article : Google Scholar : PubMed/NCBI
19	Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR and Parfitt AM: Standardized nomenclature, symbols and units for bone histomorphometry: A 2012 update of the report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res. 28:2–17. 2013. View Article : Google Scholar : PubMed/NCBI
20	Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315–323. 1999. View Article : Google Scholar : PubMed/NCBI
21	Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
22	Kazafeos K: Incretin effect: GLP-1, GIP, DPP4. Diabetes Res Clin Pract. 93 Suppl 1:S32–S36. 2011. View Article : Google Scholar : PubMed/NCBI
23	Nuche-Berenguer B, Portal-Núñez S, Moreno P, González N, Acitores A, López-Herradón A, Esbrit P, Valverde I and Villanueva-Penacarrillo ML: Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor. J Cell Physiol. 225:585–592. 2010. View Article : Google Scholar : PubMed/NCBI
24	Nuche-Berenguer B, Lozano D, Gutierrez-Rojas I, Moreno P, Marinoso ML, Esbrit P and Villanueva-Penacarrillo ML: GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol. 209:203–210. 2011. View Article : Google Scholar : PubMed/NCBI
25	Nuche-Berenguer B, Moreno P, Portal-Nuñez S, Dapía S, Esbrit P and Villanueva-Penacarrillo ML: Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states. Regul Pept. 159:61–66. 2010. View Article : Google Scholar : PubMed/NCBI
26	Nuche-Berenguer B, Moreno P, Esbrit P, Dapia S, Caeiro JR, Cancelas J, Haro-Mora JJ and Villanueva-Penacarrillo ML: Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic and insulin-resistant states. Calcif Tissue Int. 84:453–461. 2009. View Article : Google Scholar : PubMed/NCBI
27	Tantikanlayaporn D, Wichit P, Weerachayaphorn J, Chairoungdua A, Chuncharunee A, Suksamrarn A and Piyachaturawat P: Bone sparing effect of a novel phytoestrogen diarylheptanoid from Curcuma comosa Roxb. in ovariectomized rats. PLoS One. 8:e787392013. View Article : Google Scholar : PubMed/NCBI
28	Takano-Yamamoto T and Rodan GA: Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats. Proc Natl Acad Sci USA. 87:2172–2176. 1990. View Article : Google Scholar : PubMed/NCBI
29	Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y and Inagaki N: The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology. 149:574–579. 2008. View Article : Google Scholar : PubMed/NCBI
30	Peng J, Hui K, Hao C, Peng Z, Gao QX, Jin Q, Lei G, Min J, Qi Z, Bo C, et al: Low bone turnover and reduced angiogenesis in streptozotocin-induced osteoporotic mice. Connect Tissue Res. 57:277–289. 2016. View Article : Google Scholar : PubMed/NCBI
31	Yu SG, Zhang CJ, Xu XE, Sun JH, Zhang L and Yu PF: Ursolic acid derivative ameliorates streptozotocin-induced diabestic bone deleterious effects in mice. Int J Clin Exp Pathol. 8:3681–3690. 2015.PubMed/NCBI
32	Ma B, Zhang Q, Wu D, Wang YL, Hu YY, Cheng YP, Yang ZD, Zheng YY and Ying HJ: Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta Pharmacol Sin. 33:479–489. 2012. View Article : Google Scholar : PubMed/NCBI
33	Sato T, Watanabe K, Masuhara M, Hada N and Hakeda Y: Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone and IL-7 enhances generation of osteoclast precursors in vitro. J Bone Miner Metab. 25:19–27. 2007. View Article : Google Scholar : PubMed/NCBI